Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 1—January 2017

CME ACTIVITY - Research

Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010

Xizhong Cui1, Leisha D. Nolen1, Junfeng Sun, Malcolm Booth, Lindsay Donaldson, Conrad P. Quinn, Anne E. Boyer, Katherine A. Hendricks, Sean Shadomy, Pieter Bothma, Owen Judd, Paul McConnell, William A. Bower, and Peter Q. EichackerComments to Author 
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (X. Cui, J. Sun, P.Q. Eichacker); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L.D. Nolen, C.P. Quinn, A.E. Boyer, K. Hendricks, S. Shadomy, W.A. Bower); Glasgow Royal Infirmary, Glasgow, UK (M. Booth, L. Donaldson); James Paget University Hospital, Norfolk, UK (P. Bothma); Royal Derby Hospital, Derby, UK (O. Judd); Crosshouse Hospital, Kilmarnock, UK (P. McConnell)

Main Article

Figure 3

Individual LF levels (nanograms per milliliter) in 12 anthrax patients receiving AIG-IV from 10 h before until 50 h after treatment administration, Scotland, UK, 2009–2010. AIG-IV, anthrax immune hlobulin intravenous; LF, lethal factor.

Figure 3. Individual LF levels (nanograms per milliliter) in 12 anthrax patients receiving AIG-IV from 10 h before until 50 h after treatment administration, Scotland, UK, 2009–2010. AIG-IV, anthrax immune hlobulin intravenous; LF, lethal factor.

Main Article

1These authors contributed equally to this article.

TOP